Trials / Completed
CompletedNCT02905240
Saline-Controlled Study of nSTRIDE APS for Knee Osteoarthritis
A Multicenter, Double-Blind, Randomized, Saline-Controlled Study of a Single, Intra-articular Injection of Autologous Protein Solution in Patients With Knee Osteoarthritis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 332 (actual)
- Sponsor
- Zimmer Biomet · Industry
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A double-blind, multicenter, randomized, controlled trial (RCT) that will evaluate the efficacy of a single dose of Autologous Protein Solution (APS) in patients with Osteoarthritis (OA) of the knee.
Detailed description
A double-blind, multicenter, randomized, saline-controlled trial (RCT) that will evaluate the efficacy of a single dose of Autologous Protein Solution (APS) in patients with symptomatic osteoarthritis (OA) of the knee who have not been able to get satisfactory pain relief with prior treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | nSTRIDE APS | single intra-articular injection |
| DEVICE | Saline | single intra-articular injection |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2019-07-01
- Completion
- 2020-06-01
- First posted
- 2016-09-19
- Last updated
- 2023-11-07
- Results posted
- 2023-10-19
Locations
27 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT02905240. Inclusion in this directory is not an endorsement.